Exenatide vs Tesamorelin
Side-by-side comparison of key properties, dosing, and research.
GLP-1 / Weight Loss AgonistsCognitive Enhancement
ExenatideGrowth Hormone PeptidesFat Loss & Metabolic
Tesamorelin- Summary
- Exenatide is a GLP-1 receptor agonist derived from the Gila monster lizard peptide exendin-4, with 53% homology to human GLP-1 and natural resistance to DPP-4 degradation. Available as twice-daily (Byetta) or once-weekly (Bydureon) formulation, it is also being studied for Parkinson's disease neuroprotection.
- Tesamorelin is an FDA-approved synthetic GHRH analog specifically indicated for reduction of excess abdominal (visceral) fat in HIV patients with lipodystrophy. It is the only GHRH peptide with FDA approval for a fat-reduction indication and is studied off-label for metabolic syndrome and cognitive function.
- Half-Life
- ~2.4 hours (Byetta/twice-daily); Bydureon BCISE: weekly via microsphere release
- ~26 minutes
- Admin Route
- SubQ
- SubQ
- Research
- —
- —
- Typical Dose
- 5 mcg, titrate to 10 mcg
- 2 mg
- Frequency
- Twice daily
- Once daily
- Key Benefits
- Blood glucose control in type 2 diabetes
- Weight loss (average 2–3 kg in clinical trials)
- Once-weekly extended-release formulation available
- Reduces appetite and food intake
- Possible neuroprotective in Parkinson's disease (Phase II trials)
- Reduces systemic inflammation
- May protect pancreatic beta cells
- Cardiovascular neutral or potentially protective
- FDA-approved for visceral fat reduction in HIV lipodystrophy
- Significant reduction in trunk/visceral fat (average 15–20% in trials)
- Improved triglyceride and lipid profiles
- Potential cognitive benefits and memory improvement
- Preserves lean mass while reducing fat
- Natural pulsatile GH stimulation
- Side Effects
- Nausea (most common, especially initially)
- Vomiting
- Diarrhea
- Headache
- +4 more
- Injection site reactions (redness, irritation)
- Arthralgia and joint pain
- Peripheral edema
- Carpal tunnel syndrome
- +2 more
- Stacks With
- —
- —